Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1
Human Cell · 2024
DOI: 10.1007/s13577-024-01152-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Rei Noguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. Hauptthemen laut MEDLINE: Chondrosarcoma, Bone Neoplasms. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Chondrosarcoma (CS) is a malignant tumor that produces cartilaginous matrix and is the second most common primary bone sarcoma. CS encompasses a range of histological subtypes, with high-grade conventional central CS being particularly rare, occurring at a rate of 1.81 cases per 1 million person-years. Complete surgical resection is the standard curative treatment for this subtype, as radiation therapy and chemotherapy have proven ineffective. High-grade conventional central CS is highly metastatic and prone to recurrence, resulting in a poor prognosis. Therefore, effective multidisciplinary treatment strategies are urgently needed. Patient-derived cell lines offer promising tools for exploring new therapeutic approaches. However, only two cell lines of high-grade CSs are currently available in public cell banks. In this study, we aimed to establish a novel cell line for high-grade conventional central CS. We successfully developed the NCC-CS1-C1 cell line using surgically resected tumor tissues from a patient with conventional central grade 3 CS. This cell line harbored an IDH1 mutation (p.R132S), commonly found in 50% of CS cases, and exhibited complex copy number variants. A high-throughput screening of 221 anti-cancer drugs identified five candidates-bortezomib, carfilzomib, doxorubicin, panobinostat, and romidepsin-that demonstrated low IC50 values, indicating potential efficacy in treating CS. These findings suggest that NCC-CS1-C1 is a valuable tool for both preclinical and basic research on high-grade conventional central CS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
- Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
- Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
- Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. takondo@ncc.go.jp.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Noguchi, R., Ono, T., Osaki, J., Adachi, Y., Iwata, S., Shiota, Y., Yanagihara, K., Nishino, S., Funada, T., Ogura, K., Yoshida, A., Kawai, A., & Kondo, T. (2024). Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1. Human Cell. https://doi.org/10.1007/s13577-024-01152-0
Vancouver
Noguchi R, Ono T, Osaki J, Adachi Y, Iwata S, Shiota Y, et al. Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1. Human Cell. 2024. doi:10.1007/s13577-024-01152-0
BibTeX
@article{Noguchi2024,
author = {Noguchi, Rei and Ono, Takuya and Osaki, Julia and Adachi, Yuki and Iwata, Shuhei and Shiota, Yomogi and Yanagihara, Kazuyoshi and Nishino, Shogo and Funada, Takaya and Ogura, Koichi and Yoshida, Akihiko and Kawai, Akira and Kondo, Tadashi},
title = {Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1},
journal = {Human Cell},
year = {2024},
doi = {10.1007/s13577-024-01152-0}
}
EUVIMED